The estimated Net Worth of Molly Henderson is at least $2.03 million dollars as of 15 July 2024. Ms Henderson owns over 4,325 units of UroGen Pharma Ltd stock worth over $1,373,363 and over the last 6 years she sold URGN stock worth over $376,605. In addition, she makes $279,336 as Chief Financial Officer at UroGen Pharma Ltd.
Sign up
Ms MBA URGN stock SEC Form 4 insiders trading
Ms has made over 14 trades of the UroGen Pharma Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 4,325 units of URGN stock worth $50,689 on 15 July 2024.
The largest trade she's ever made was selling 12,492 units of UroGen Pharma Ltd stock on 1 November 2023 worth over $110,929. On average, Ms trades about 1,818 units every 39 days since 2018. As of 15 July 2024 she still owns at least 99,447 units of UroGen Pharma Ltd stock.
You can see the complete history of Ms Henderson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Molly Henderson CPA, MBA biography
Molly Henderson CPA, MBA is the Chief Financial Officer at UroGen Pharma Ltd.
What is the salary of Ms MBA?
As the Chief Financial Officer of UroGen Pharma Ltd, the total compensation of Ms MBA at UroGen Pharma Ltd is $279,336. There are 13 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
How old is Ms MBA?
Ms MBA is 50, she's been the Chief Financial Officer of UroGen Pharma Ltd since . There are 11 older and 4 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
What's Ms MBA's mailing address?
Molly's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM, NJ, 07932.
Insiders trading at UroGen Pharma Ltd
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun et Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
What does UroGen Pharma Ltd do?
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
What does UroGen Pharma Ltd's logo look like?
Complete history of Ms Henderson stock trades at Ayala Pharmaceuticals, UroGen Pharma Ltd et Phathom Pharmaceuticals Inc
UroGen Pharma Ltd executives and stock owners
UroGen Pharma Ltd executives and other stock owners filed with the SEC include:
-
Elizabeth Barrett,
President, Chief Executive Officer, Director -
Elizabeth A. Barrett,
Pres, CEO & Director -
Mark Schoenberg,
Chief Medical Officer -
Ron Bentsur,
Advisor -
Dr. Mark P. Schoenberg,
Chief Medical Officer -
Arie Belldegrun,
Independent Chairman of the Board -
Jason Drew Smith,
Gen. Counsel & Chief Compliance Officer -
Cynthia Butitta,
Independent Director -
Kathryn Falberg,
Independent Director -
Stuart Holden,
Independent Director -
Ran Nussbaum,
Independent Director -
Fred Cohen,
Independent Director -
Shawn Tomasello,
Independent Director -
Molly Henderson CPA, MBA,
Chief Financial Officer -
Elyse Seltzer,
Chief Development Officer -
Polly Murphy,
Chief Business Officer -
Jeff Bova,
Chief Commercial Officer -
Jason Smith,
Chief Compliance Officer, General Counsel -
Jim Ottinger,
Executive Vice President, Regulatory Affairs and Quality -
Marina Konorty,
Executive Vice President, Research & Development and Technical Operations -
Molly Henderson,
Chief Financial Officer, Principal Accounting Officer -
James Ottinger R.ph.,
Exec. VP of Regulatory Affairs & Quality -
Jeffrey Bova M.B.A.,
Chief Commercial Officer -
Dr. Sari Prutchi-Sagiv Ph.D.,
Marketing Director -
Eric Van Zanten,
Sr. Director of Communications -
Jason Smith,
Gen. Counsel & Chief Compliance Officer -
Sara Blum Sherman,
Sr. Director of Investor Relations -
James A. Jr. Robinson,
Director -
Investments Iv, L.P.Pro Que...,
-
Stephen Mullennix,
Chief Operating Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Leana Wen,
Director -
Dong Kim,
Chief Financial Officer -
Daniel George Wildman,
Director